ketanserin has been researched along with Atrophy in 1 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Svarer, C | 1 |
| Madsen, K | 1 |
| Hasselbalch, SG | 1 |
| Pinborg, LH | 1 |
| Haugbøl, S | 1 |
| Frøkjaer, VG | 1 |
| Holm, S | 1 |
| Paulson, OB | 1 |
| Knudsen, GM | 1 |
1 trial available for ketanserin and Atrophy
| Article | Year |
|---|---|
MR-based automatic delineation of volumes of interest in human brain PET images using probability maps.
Topics: Aged; Aged, 80 and over; Aging; Algorithms; Atrophy; Brain; Brain Mapping; Cognition Disorders; Fema | 2005 |